Introduction
Guillain-Barre Syndrome (GBS) is a progressive immune-related polyradiculoneuropathy that is the most common cause of acute and progressive generalized paralysis (1) . There is still little knowledge on the biochemical and immunological markers that can be used to support the diagnosis of GBS. Most patients (60% to 70%) have a history of surgical intervention, vaccination or infections, such as an upper respiratory or gastrointestinal infection, that often predate the onset of neurological symptoms by 4 weeks (2).
Several clinical subtypes of GBS have been identified, such as including acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), acute motor-sensory axonal neuropathy (AMSAN), Miller Fisher Syndrome (MFS), acute pandysautonomia and acute sensory neuropathy (3).
Both cell-mediated immunity and humoral mechanisms are involved in the pathogenesis (4, 5) .
The effectiveness of plasmapheresis and intravenous immunoglobulin (IVIg) was demonstrated in randomized trials (6, 7) .Recently, the blood neutrophil-to-lymphocyte ratio (NLR) has been studied as a biomarker for systemic inflammation in a number of neurological disorders (8) (9) (10) and was found to be associated with a poor prognosis in certain diseases (11) . Considering the integral role of inflammation in the development of GBS, we focused on three systemic inflammation markers in affected patients, namely the neutrophil-to-lymphocyte ratio, C-reactive protein (CRP) levels and erythrocyte sedimentation rate (ESR). To our best knowledge, NLR has not been previously studied in GBS patients.
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Medical Science and Discovery, 2016; 3(8):305- 11 Thus, in the current study, we aimed to determine the predictive value of NLR, CRP and ESR in the diagnosis of GBS during the acute phase and to investigate the correlation of NLR with the severity and subtype of the disease, as well as the role of the response to IVIg treatment in GBS patients.
Material and Methods

Study population:
This study is a hospital-based retrospective investigation. Study approval was obtained from the Ethics Committee of Gaziantep University Faculty of Medicine, Turkey. Electronic medical records of 124 patients who were diagnosed with GBS (according to Asbury and Cornblath's diagnostic criteria) (12) . 19 at an inpatient clinic of neurology (Department of Neurology, Gaziantep University Sahinbey Research Hospital, Gaziantep/Turkey) between January 2008 and January 2015 were reviewed retrospectively. Patients who were subsequently diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP) during follow-up visits after being hospitalized with GBS were excluded. Additionally, patients with a history of alcoholism, diabetes mellitus or exposure to toxic substances, metals or drugs that could cause acute neuropathy and patients with inadequate data were excluded.
Thus, 94 eligible patients not meeting these exclusion criteria were enrolled. The data reviewed for study patients included age, gender, history of antecedent infections, signs of infection at the time of admission (based on clinical and blood parameters), electrophysiological findings, clinical features, information related to treatment, and duration of hospitalization. All GBS patients were classified electro physiologically as AIDP, AMAN or AMSAN using motor nerve conduction criteria (13) . The GBS disability score (Hughes grade scale) was used to evaluate the disease severity during hospitalization and the first outpatient appointment (ranging from 3 weeks to 1 month after discharge )(14). Venous blood values at the time of presentation (within a mean period of 5.4±2.7 days after the onset of symptoms (min: 1, max: 15) and those obtained at the first occasion following administration of IVIG (0.4 g/kg/day continuously for 5 days) treatment (min: 2 and max: 10 days) for any reason were recorded for all patients. Sixteen (17%) patients treated with plasmapheresis after IVIg treatment because of a worsened neurological examination, despite receiving IVIg treatment.
A second set of blood samples were taken before the plasmapheresis. Post-treatment hemogram values were available for all 94 patients, but only 22 patients had both CRP and ESR values available; thus, only post-treatment NLR values were recorded. Healthy controls (n=101) matched for age and gender who were admitted to our hospital for routine check-up were randomly chosen from the hospital database if they did not have any symptoms of peripheral neuropathy, clinical signs or laboratory findings suggestive of an infection or a history of chronic illnesses, malignancy or rheumatic disorders.
ESR was measured using the traditional Westergren method. CRP levels were quantified using a nephelometric assay on a Dade Behring Nephelometer BN II device (Siemens Healthcare GmbH, Erlangen, Germany). CBC analysis was performed with a Beckman Coulter (High Wycombe, UK) Gen-S automated analyser within 2 hours of blood sampling. NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count in a complete blood count taken before and after IVIg treatment.
Statistical Method:
Student's t-test was used to compare normally distributed numerical variables in two independent groups, and the Mann-Whitney U test was used for non-normally distributed numerical variables. An ANOVA and Fisher's least significant difference (LSD) multi-comparison test were employed to compare normally distributed variables in more than two groups, whereas the Kruskal-Wallis test was used for non-normally distributed variables. Pearson's coefficient of correlation was used to test correlations between numerical variables, and a chi-square test was used for the analysis of correlations between categorical variables.
Receiver operating characteristic (ROC) curves were used to determine the cutoff values for NLR. For descriptive statistics, data are presented as the mean ± standard deviation for numerical variables and the number and percentage for categorical variables. SPSS for Windows version 22.0 software package was used for statistical analyses, and a p value less than 0.05 was considered statistically significant.
Results:
The study enrolled a total of 94 GBS patients, including 32 females and 62 males with a mean age of 48.7±20.6 years (18-86). The control group consisted of a total of 101 healthy individuals (47 females, 54 males) with a mean age of 50.63±19.025 years . The demographic data, clinical characteristics and blood biochemistry values of the study population are summarized in Table I .
Electrophysiological classification of the GBS patients revealed the following subtypes: AIDP ( = 64), AMAN ( = 16) and AMSAN ( = 14). The mean duration from the onset of symptoms to the confirmed diagnosis of GBS was 5.4±2.7 days (1-15). The mean Hughes score of patients at the initial examination was 3.53±0.49. Significantly reduced NLR values were found after IVIg treatment among patients (p=0.001) ( Table I ).
The mean CRP value for patients at presentation (16.3±14.2 mg/dl) was significantly higher compared to that for the control group (3.7±1.2 mg/dl; p=0.001). Similar findings were also observed for ESR (Table I) . When patients were divided into two subgroups based on the IVIg treatment response, the patients unresponsive to IVIg therapy showed significantly higher NLR values at presentation compared with the treatment-responsive patients (p=0.001) (Table II) .
At presentation, the mean Hughes score was 3.48±0.38 for patients responding to IVIg and 3.69±0.72 for non-responsive patients, but the difference was not statistically significant (p=0.149). When we classified the patients according to the demyelinating form (AIDP) and axonal form (AMAN and AMSAN) subtypes, we observed the application HGS was higher in the axonal form (p=0.001). NLR values at presentation did not differ significantly between the disease subtypes (p=0.252). Eleven (11.7%) patients had signs of infection (both clinical and laboratory) at presentation, and a significant difference was found between the mean NLR values of infected patients (9.54±5.98) and non-infected patients (5.15±3.94) at presentation (p=0.001). CRP and ESR showed similar findings (Table III) .
Based on the medical history, among the patients with clinical signs of infection at presentation, 31 patients (32.9%) had experienced an URTI and 17 (18.1%) patients had experienced diarrhoea within the last month. Patients with a history of infection had a mean NLR of 6.16±4.3, which did not differ significantly from the mean NLR of patients without such a history (4.60±3.80; p=0.009).
Analyses for the correlation between the disease severity and NLR revealed a significant positive correlation for patients between HGS at presentation and NLR values at presentation (r=0.383, p=0,000). A significant positive correlation was also found between the HGS at the follow-up visit within 3 weeks to 1 month after discharge and NLR at presentation (r=0.363 p=0,000). There was a mean improvement of 1.44 points in the HGS following treatment, and a significant negative correlation was observed between the magnitude of improvement in HGS and NLR values at presentation and posttreatment (r=-0.312 p= 0.002 and r=-0.288, p= 0.005, respectively). The application NLR was positively correlated and significantly associated with the length of the hospital stay (r=0.296; p=0.004). NLR at presentation was significantly associated and positively correlated with CRP and ESR at presentation (r=0.351, p=0.001 and r=0.338, p=0.001, respectively).
As determined by the ROC analysis, a NLR value of 3.5 had a 62.8% sensitivity and 90.1% specificity for predicting GBS (the area under curve (AUC), 0.772±0.035; p<0.001). A CRP value of 11 had a 52.7% sensitivity and an 86% specificity for predicting GBS (AUC=0.717±0.0374; p<0.001). An ESR value of 12.3 had a 51.3% sensitivity and an 82% specificity for predicting GBS (AUC=0.698±0.312; p=0,003) ( Figure I ).
Exclusion of 11 patients with signs of infection at presentation yielded a NLR value of 3.2, which was associated with a 61.6% sensitivity and an 89.8% specificity for predicting GBS (AUC= 0.752±0.031, p<0.001). In these patients, A CRP value of 7.5 had a 48.7% sensitivity and 63% specificity for predicting GBS (AUC=0.645±0.0305; p=0.105). An ESR value of 8.3 had a 46.3% sensitivity and 61% specificity for predicting GBS (AUC= 0.612±0.0317; p=0.137) ( Figure II) .
Discussion
Based on the results of this study, we found that NLR values were significantly higher in GBS patients than in healthy controls. A NLR value of 3.5 predicted the presence of GBS with a 62.8% sensitivity and 90.1% specificity. The cutoff value for the NLR for predicting GBS, regardless of infection, was 3.2 with a 61.6% sensitivity and an 89.8% specificity.
GBS is an acute inflammatory process that involves the peripheral nerves and nerve roots, and both humoral and cell-mediated immunity mechanisms play an integral role in its pathogenesis (5) . Recently, NLR has been recognized as a simple and cost-effective peripheral biomarker that indicates the inflammatory status because it is believed to reflect the numerical balance between neutrophils and lymphocytes in the blood (9, 10, 15, 16) . CRP and ESR are elevated in the event of systemic inflammation, and combined use of ESR and CRP was considered to be more appropriate as inflammatory markers (17) .
In the present study, GBS patients had significantly higher NLR, CRP and ESR values compared to healthy controls at presentation. These parameters are known to be influenced by infection (18) . Therefore, when we removed the patients with clinical or laboratory signs of infection, the predictive significance of CRP and ESR disappeared, but an NLR value of 3.2 showed a 61.6% sensitivity and an 89.8% specificity for predicting GBS that remained significant.
Recent studies demonstrated that NLR can be used as a marker of disease, but it may also predict the disease severity and a poor prognosis (9, 10, 11, 15, 19) . Similarly, positive correlations were found among the initial NLR, the initial Hughes scores, and the length of hospital stay. However, it was expected that patients with a high HGS would have a long hospital stay. There was a 1.44-point average improvement after treatment. NLR at presentation showed a significant negative correlation with an improvement in the Hughes scores. Thus a high NLR may be correlated with a slow recovery. Also, the NLR values of IVIg treatment-resistant patients were higher regardless of the disease severity.
Especially in the axonal form, more cranial nerve involvement and a more rapid and severe need for mechanical ventilation was reported (20). In our study, patients with the axonal form had higher HGS at initiation and discharge.
Despite the current positive correlation with disease severity and NLR, there were no significant differences between subgroups. This may be due to different pathogenesis of subtypes of disease. 
Conclusion
Our study has several limitations. This study used a retrospective design and a small sample size. A major limitation of our study was the failure to obtain follow-up blood samples from all patients at a prespecified time point because they differed in the time of admission and transport to the emergency room. Nevertheless, to the best of our knowledge, the present study is the first to investigate the relationship between NLR and GBS. Unlike ESR and CRP, NLR might be a promising marker in GBS, regardless of infection. Another value, the average for NLR, is an inexpensive, quick and easy measure to obtain, and it might be associated with the severity of the disease..
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